Device Trial Radar · NCT06567483
A Comparison of Protein-bound and Large Molecular Weight Uremic Toxin Removals With Novel Super High-flux Dialyzer Between Hemodialysis and High Volume Online HDF Modalities
Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 1, 2023
Primary completion
Mar 1, 2024
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- Chulalongkorn UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this prospective, randomized, crossover study is to study about using super high-flux dialyzer in the chronic hemodialysis patients. The main questions aim to answer are the reduction ratio of protein bound uremic toxins Participants will undergone the pre-dilution online hemodiafiltration and conventional hemodialysis for each 8 weeks followed by washout phase for 4 weeks.
Conditions
- Uremic; Toxemia
Interventions
ELISIO21HXDevice
Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Protein bound uremic toxin reduction ratio (percent)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculty of Medicine Chulalongkorn university
Pathum Wan, Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.